Senseonics (NYSE:SENS) Stock Price Up 6.2% - Should You Buy?

Senseonics Holdings, Inc. (NYSE:SENS - Get Free Report)'s stock price shot up 6.2% during mid-day trading on Monday . The company traded as high as $0.90 and last traded at $0.90. 1,711,615 shares traded hands during trading, a decline of 88% from the average session volume of 14,655,776 shares. The stock had previously closed at $0.85.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on SENS shares. HC Wainwright reiterated a "buy" rating and issued a $2.00 target price on shares of Senseonics in a research note on Wednesday. StockNews.com started coverage on shares of Senseonics in a research report on Thursday, December 26th. They issued a "sell" rating on the stock.

Senseonics Trading Down 5.1 %

The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. The stock has a market capitalization of $347.08 million, a P/E ratio of -4.52 and a beta of 1.17. The firm's 50-day simple moving average is $0.86 and its 200 day simple moving average is $0.53.

Senseonics (NYSE:SENS - Get Free Report) last announced its earnings results on Monday, March 3rd. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.09). Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. During the same period last year, the business earned ($0.07) EPS. Equities research analysts anticipate that Senseonics Holdings, Inc. will post -0.14 EPS for the current fiscal year.

Remove Ads

Insider Transactions at Senseonics

In other news, CFO Frederick T. Sullivan purchased 124,933 shares of the company's stock in a transaction dated Thursday, December 12th. The shares were bought at an average price of $0.38 per share, with a total value of $47,474.54. Following the completion of the transaction, the chief financial officer now directly owns 2,478,844 shares in the company, valued at $941,960.72. This trade represents a 5.31 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Timothy T. Goodnow purchased 315,000 shares of the firm's stock in a transaction on Tuesday, December 10th. The shares were purchased at an average price of $0.31 per share, with a total value of $97,650.00. Following the completion of the acquisition, the chief executive officer now directly owns 11,310,355 shares of the company's stock, valued at approximately $3,506,210.05. This trade represents a 2.86 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is owned by insiders.

Institutional Trading of Senseonics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP bought a new position in Senseonics during the fourth quarter valued at about $36,000. Millennium Management LLC raised its stake in Senseonics by 299.0% during the fourth quarter. Millennium Management LLC now owns 1,088,029 shares of the company's stock worth $569,000 after acquiring an additional 815,332 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Senseonics by 6,694.1% during the fourth quarter. Jane Street Group LLC now owns 6,118,786 shares of the company's stock valued at $3,203,000 after acquiring an additional 6,028,726 shares during the period. First Light Asset Management LLC acquired a new stake in shares of Senseonics in the 4th quarter valued at $3,366,000. Finally, Northern Trust Corp grew its holdings in shares of Senseonics by 11.2% in the 4th quarter. Northern Trust Corp now owns 1,194,960 shares of the company's stock worth $625,000 after purchasing an additional 120,441 shares during the last quarter. Institutional investors and hedge funds own 12.36% of the company's stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.